Loading...
XNASSVRA
Market cap523mUSD
Jan 07, Last price  
3.05USD
1D
0.00%
1Q
-16.44%
Jan 2017
-49.80%
Name

Savara Inc

Chart & Performance

D1W1MN
XNAS:SVRA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.76%
Rev. gr., 5y
25.99%
Revenues
0k
0496,0590500,000500,000300,000488,9590001,54854400,000000257,000000
Net income
-55m
L+40.45%
-6,701,048-24,782,646-29,331,773-22,142,040-26,647,493-11,325,058-8,450,922-13,260,000-15,559,489-21,480,285-28,702,000-39,842,000-10,923,000-29,797,000-61,516,000-105,025,000-51,097,000-45,296,000-38,946,000-54,698,000
CFO
-51m
L+47.77%
-5,175,390-11,646,829-15,773,544-19,643,190-23,787,604-12,616,416-8,341,237-13,466,954-13,918,868-17,788,962-24,645,000-32,949,000-8,370,000-28,234,000-39,275,000-45,123,000-39,836,000-40,081,000-34,554,000-51,061,000
Earnings
Mar 05, 2025

Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
URL
http://savarapharma.com/
IPO date
Jun 25, 2001
Employees
28
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
104,192
38,975
Unusual Expense (Income)
NOPBT
(104,192)
(38,975)
NOPBT Margin
Operating Taxes
796
Tax Rate
NOPAT
(104,192)
(39,771)
Net income
(54,698)
40.45%
(38,946)
-14.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
82,497
(1,000)
BB yield
-10.62%
0.00%
Debt
Debt current
143
64
Long-term debt
26,491
26,142
Deferred revenue
Other long-term liabilities
247
54
Net debt
(135,685)
(99,670)
Cash flow
Cash from operating activities
(51,061)
(34,554)
CAPEX
(296)
(9)
Cash from investing activities
(57,116)
52,645
Cash from financing activities
82,780
87
FCF
(104,411)
(39,749)
Balance
Cash
162,319
125,876
Long term investments
Excess cash
162,319
125,876
Stockholders' equity
(393,500)
(339,160)
Invested Capital
560,610
473,134
ROIC
ROCE
EV
Common stock shares outstanding
165,205
152,772
Price
4.70
203.23%
1.55
25.00%
Market cap
776,462
227.90%
236,796
42.60%
EV
640,777
137,126
EBITDA
(104,017)
(38,808)
EV/EBITDA
Interest
88
Interest/NOPBT